首页> 外文期刊>Pharmacological reviews >International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.
【24h】

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

机译:国际基础和临床药理学联盟。 LXXV。 G蛋白偶联褪黑激素受体的命名,分类和药理作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs. In the circulation, the concentration of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors. Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiology and behavior. The melatonin message is translated through activation of two G protein-coupled receptors, MT(1) and MT(2), that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer. This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues. The pharmacological and molecular properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a number of illnesses, including sleep disorders, depression, and cancer.
机译:褪黑激素(5-甲氧基-N-乙酰基色胺)主要在松果体和视网膜以及一些外围组织和器官中合成。在循环中,褪黑激素的浓度遵循昼夜节律,夜间高水平的褪黑激素为具有褪黑激素受体的靶组织提供定时提示。褪黑激素受体接收并翻译褪黑激素的信息,以影响生理和行为的日常和季节性节律。褪黑激素信息是通过激活两个G蛋白偶联受体MT(1)和MT(2)来翻译的,它们是失眠和昼夜节律失调,抑郁症,心血管疾病和癌症等疾病的潜在治疗靶标。这篇综述总结了自1958年亚伦·勒纳(Aaron Lerner)发现褪黑激素以功能表征,克隆和定位哺乳动物组织中的受体以来采取的步骤。描述了受体的药理和分子特性,以及目前发现和开发用于治疗许多疾病的配体的努力,这些疾病包括睡眠障碍,抑郁症和癌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号